Our Trainees assist researchers in finding results in the latest area of addiction research.
Dr. Lawrence M Carey is postdoctoral fellow working under the supervision of Dr. Charles P France. His research is focused on leveraging the power of synthetic- and phytocannabinoid agents to decrease problematic side effects associated with the use of opioid analgesics (dependence, tolerance and abuse). His future goals are to gain employment as a professor at a major research institution and conduct research into novel pharmacological strategies to combat pathological pain and substance abuse disorders.
Dr. Carey received his bachelors degree in Psychology from Northern Michigan University in 2012, where he conducted research into novel pharmacotherapies for the treatment of affective disorders in rodents. He completed his PhD in the lab of Dr. Andrea Hohmann at Indiana University Bloomington where he conducted research into novel treatment mechanisms for the management of pathological pain. A main focus of his doctoral work centered on unraveling the complexities of cannabinoid pharmacology with a focus on targeting cannabinoid CB2 receptors as a therapeutic target to produce pain relief and decrease opioid antinociceptive tolerance and physical dependence.
Li AL, Lin X, Dhopeshwarkar AS, Thomaz AC, Carey LM, Liu Y, Nikas SP, Makriyannis A, Mackie K, Hohmann AG. (2019). Cannabinoid CB2 Agonist AM1710 Differentially Suppresses Distinct Pathological Pain States and Attenuates Morphine Tolerance and Withdrawal. Mol Pharmacol. PMID30504240.
Lee WH, Carey LM, Li LL, Xu Z, Lai YY, Courtney MJ, Hohmann AG. (2018). ZLc002, a putative small-molecule inhibitor of nNOS interaction with NOS1AP, suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with paclitaxel to reduce tumor cell viability. Mol Pain. PMID30157705.
Panoz-Brown D, Iyer V, Carey LM, Sluka CM, Rajic G, Kestenman J, Gentry M, Brotheridge S, Somekh I, Corbin HE, Tucker KG, Almeida B, Hex SB, Garcia KD, Hohmann AG, Crystal JD. (2018). Replay of Episodic Memories in the Rat. Curr Biol. PMID29754898.
Panoz-Brown D, Carey LM, Smith AE, Gentry M, Sluka CM, Corbin HE, Wu JE, Hohmann AG, Crystal JD. (2017). The chemotherapeutic agent paclitaxel selectively impairs reversal learning while sparing prior learning, new learning and episodic memory. Neurobiol Learn Mem. PMID28811227.
Carey LM, Rice RJ, Prus AJ. (2017). The Neurotensin NTS1 Receptor Agonist PD149163 Produces Antidepressant-Like Effects in the Forced Swim Test: Further Support for Neurotensin as a Novel Pharmacologic Strategy for Antidepressant Drugs. Drug Dev Res. PMID28736839.
Li AL, Carey LM, Mackie K, Hohmann AG. (2017). Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. PMID28592614.
Carey LM, Gutierrez T, Deng L, Lee WH, Mackie K, Hohmann AG. (2017). Inflammatory and Neuropathic Nociception is Preserved in GPR55 Knockout Mice. Sci Rep. PMID28428628.
Carey LM, Lee WH, Gutierrez T, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. (2017). Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. Neuroscience. PMID28285942.
Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG. (2016). A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase. Mol Pain. PMID27178246.
Prus AJ, Schuck CJ, Rusch KR and Carey LM. (2014). The discriminative stimulus effects of the neurotensin NTS1 receptor agonist PD149163 in rats: stimulus generalization testing with dopamine D1 and D2 receptor ligands. Drug Dev Res. PMID24668440.